Dossier assessment
Sipavibart (pre-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sipavibart (pre-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sipavibart (pre-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Pre-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older weighing at least 40 kg and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments
Added benefit not proven
Project details
- Project no.
- A25-28
- Commission
- Commission awarded on 13.02.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-28_en
Connected Projects
-
Addendum
Sipavibart (pre exposure prophylaxis of COVID 19) – Addendum to Project A25-28
Status: Commission completed
-
Addendum
Sipavibart (pre exposure prophylaxis of COVID 19) – 2nd Addendum to Project A25-28
Status: Commission completed